BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36769161)

  • 1. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
    Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.
    Xu T; Vorobyeva A; Schulga A; Konovalova E; Vorontsova O; Ding H; Gräslund T; Tashireva LA; Orlova A; Tolmachev V; Deyev SM
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
    Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
    Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
    Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
    Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells.
    Xu T; Liu Y; Schulga A; Konovalova E; Deyev SM; Tolmachev V; Vorobyeva A
    Oncol Rep; 2022 May; 47(5):. PubMed ID: 35315504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker.
    Babaee N; Talebkhan Garoosi Y; Karimipoor M; Davami F; Bayat E; Safarpour H; Mahboudi F; Barkhordari F
    Mol Biol Rep; 2020 Oct; 47(10):7323-7331. PubMed ID: 32979162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
    Simon M; Stefan N; Borsig L; Plückthun A; Zangemeister-Wittke U
    Mol Cancer Ther; 2014 Feb; 13(2):375-85. PubMed ID: 24184633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
    Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
    Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with
    Tolmachev V; Bodenko V; Orlova A; Schulga A; Deyev SM; Vorobyeva A
    Oncol Lett; 2023 Jan; 25(1):12. PubMed ID: 36478911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2.
    Lv YF; Zhang H; Cui Z; Ma CJ; Li YL; Lu H; Wu HY; Yang JL; Cao CY; Sun WZ; Huang XF
    BMC Cancer; 2023 Dec; 23(1):1220. PubMed ID: 38082377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the use of tumor-specific DARPin-toxin fusion proteins for ex vivo purging of cancer metastases from human ovarian cortex before autotransplantation.
    Eijkenboom L; Palacio-Castañeda V; Groenman F; Braat D; Beerendonk C; Brock R; Verdurmen W; Peek R
    F S Sci; 2021 Nov; 2(4):330-344. PubMed ID: 35559858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.
    Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.
    Deyev SM; Xu T; Liu Y; Schulga A; Konovalova E; Garousi J; Rinne SS; Larkina M; Ding H; Gräslund T; Orlova A; Tolmachev V; Vorobyeva A
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.
    Stefan N; Zimmermann M; Simon M; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2014 Dec; 25(12):2144-56. PubMed ID: 25350699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
    Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
    Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer.
    van den Brand D; van Lith SAM; de Jong JM; Gorris MAJ; Palacio-Castañeda V; Couwenbergh ST; Goldman MRG; Ebisch I; Massuger LF; Leenders WPJ; Brock R; Verdurmen WPR
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted EpCAM-binding for the development of potent and effective anticancer proteins.
    Liu Z; Zhang C; Cui B; Wang Y; Lim K; Li K; Thiery JP; Chen J; Ho CL
    Biomed Pharmacother; 2023 May; 161():114443. PubMed ID: 36863098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape.
    Shramova E; Proshkina G; Shipunova V; Ryabova A; Kamyshinsky R; Konevega A; Schulga A; Konovalova E; Telegin G; Deyev S
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.